IBDEI3F8 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,57550,0)
 ;;=D68.318^^267^2880^16
 ;;^UTILITY(U,$J,358.3,57550,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57550,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Intrns Circ Anticoag,Antib,Inhib
 ;;^UTILITY(U,$J,358.3,57550,1,4,0)
 ;;=4^D68.318
 ;;^UTILITY(U,$J,358.3,57550,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,57551,0)
 ;;=R50.9^^267^2880^15
 ;;^UTILITY(U,$J,358.3,57551,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57551,1,3,0)
 ;;=3^Fever,Unspec
 ;;^UTILITY(U,$J,358.3,57551,1,4,0)
 ;;=4^R50.9
 ;;^UTILITY(U,$J,358.3,57551,2)
 ;;=^5019512
 ;;^UTILITY(U,$J,358.3,57552,0)
 ;;=R53.81^^267^2880^22
 ;;^UTILITY(U,$J,358.3,57552,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57552,1,3,0)
 ;;=3^Malaise
 ;;^UTILITY(U,$J,358.3,57552,1,4,0)
 ;;=4^R53.81
 ;;^UTILITY(U,$J,358.3,57552,2)
 ;;=^5019518
 ;;^UTILITY(U,$J,358.3,57553,0)
 ;;=R53.83^^267^2880^14
 ;;^UTILITY(U,$J,358.3,57553,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57553,1,3,0)
 ;;=3^Fatigue
 ;;^UTILITY(U,$J,358.3,57553,1,4,0)
 ;;=4^R53.83
 ;;^UTILITY(U,$J,358.3,57553,2)
 ;;=^5019520
 ;;^UTILITY(U,$J,358.3,57554,0)
 ;;=R60.0^^267^2880^12
 ;;^UTILITY(U,$J,358.3,57554,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57554,1,3,0)
 ;;=3^Edema,Localized
 ;;^UTILITY(U,$J,358.3,57554,1,4,0)
 ;;=4^R60.0
 ;;^UTILITY(U,$J,358.3,57554,2)
 ;;=^5019532
 ;;^UTILITY(U,$J,358.3,57555,0)
 ;;=R60.1^^267^2880^11
 ;;^UTILITY(U,$J,358.3,57555,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57555,1,3,0)
 ;;=3^Edema,Generalized
 ;;^UTILITY(U,$J,358.3,57555,1,4,0)
 ;;=4^R60.1
 ;;^UTILITY(U,$J,358.3,57555,2)
 ;;=^5019533
 ;;^UTILITY(U,$J,358.3,57556,0)
 ;;=R60.9^^267^2880^13
 ;;^UTILITY(U,$J,358.3,57556,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57556,1,3,0)
 ;;=3^Edema,Unspec
 ;;^UTILITY(U,$J,358.3,57556,1,4,0)
 ;;=4^R60.9
 ;;^UTILITY(U,$J,358.3,57556,2)
 ;;=^5019534
 ;;^UTILITY(U,$J,358.3,57557,0)
 ;;=R63.4^^267^2880^1
 ;;^UTILITY(U,$J,358.3,57557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57557,1,3,0)
 ;;=3^Abnormal Weight Loss
 ;;^UTILITY(U,$J,358.3,57557,1,4,0)
 ;;=4^R63.4
 ;;^UTILITY(U,$J,358.3,57557,2)
 ;;=^5019542
 ;;^UTILITY(U,$J,358.3,57558,0)
 ;;=Z79.4^^267^2880^21
 ;;^UTILITY(U,$J,358.3,57558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57558,1,3,0)
 ;;=3^Long Term Use of Insulin,Current
 ;;^UTILITY(U,$J,358.3,57558,1,4,0)
 ;;=4^Z79.4
 ;;^UTILITY(U,$J,358.3,57558,2)
 ;;=^5063334
 ;;^UTILITY(U,$J,358.3,57559,0)
 ;;=Z79.01^^267^2880^20
 ;;^UTILITY(U,$J,358.3,57559,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57559,1,3,0)
 ;;=3^Long Term Use of Anticoagulants,Current
 ;;^UTILITY(U,$J,358.3,57559,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,57559,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,57560,0)
 ;;=E10.649^^267^2880^5
 ;;^UTILITY(U,$J,358.3,57560,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57560,1,3,0)
 ;;=3^Diabetes Type 1 w/ Hypoglycemia
 ;;^UTILITY(U,$J,358.3,57560,1,4,0)
 ;;=4^E10.649
 ;;^UTILITY(U,$J,358.3,57560,2)
 ;;=^5002622
 ;;^UTILITY(U,$J,358.3,57561,0)
 ;;=E11.649^^267^2880^9
 ;;^UTILITY(U,$J,358.3,57561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57561,1,3,0)
 ;;=3^Diabetes Type 2 w/ Hypoglycemia
 ;;^UTILITY(U,$J,358.3,57561,1,4,0)
 ;;=4^E11.649
 ;;^UTILITY(U,$J,358.3,57561,2)
 ;;=^5002662
 ;;^UTILITY(U,$J,358.3,57562,0)
 ;;=E66.1^^267^2880^23
 ;;^UTILITY(U,$J,358.3,57562,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57562,1,3,0)
 ;;=3^Morbid Obesity d/t Drugs
 ;;^UTILITY(U,$J,358.3,57562,1,4,0)
 ;;=4^E66.1
 ;;^UTILITY(U,$J,358.3,57562,2)
 ;;=^5002828
 ;;^UTILITY(U,$J,358.3,57563,0)
 ;;=E66.2^^267^2880^25
 ;;^UTILITY(U,$J,358.3,57563,1,0)
 ;;=^358.31IA^4^2
